Prospective study about radiation field setting based on 18FDG-PET in definitive chemoradiation for the inoperable local advanced esophageal cancer.

Prospective study about radiation field setting based on 18FDG-PET in definitive chemoradiation for the inoperable local advanced esophageal cancer. - Radiation field setting in chemoradiation for esophageal cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007209

Enrollment

Registered

2012-02-02

Start date

2011-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophageal cancer

Interventions

Duration of chemoradiation was 6 weeks. Radiation consists of 50Gy - 50.4 Gy delivered in 1.8 Gy - 2 Gy per fraction over 5 W - 5.6 weeks. Clinical target volume was defined as the primary tumor

days 29-32, continuous. Nedaplatin consists of 80 mg/m2, day 1 &amp

day 29, bolus.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. histopathologically proven invasive esophageal cancer 2. clinical stage I without indicationf of ESD/EMR or clinical stages II - IV 3. PS: 0-2 4. written informed consent 5. WBC: 4000-12000/mm3, Neu > 2000/mm3, Plt > 100,000/mm3, Hb > 9.0g/dL, Tbil < 1.5mg/dL, GOT/GPT < 76/72U/L, Cre < 1.2mg/dL, PaO2 > 70mmHg

Exclusion criteria

Exclusion criteria: 1. having serious complications 2. having synchronism overlap cancer 3. having metastasis to other organs 4. with a history of radiation for the same lesion 5. with a history of chemothrapy 6. having administration contraindication of nedaplatin/5-FU 7. having drug hypersensitivity 8. A woman with the possibility (intention) of the pregnancy, a pregnant woman 9. charging doctor regards as inadequacy because of medical, psychologically, or other factors

Design outcomes

Primary

Measure	Time frame
Isolated lymph node relapse rate	—

Secondary

Measure	Time frame
Complete response rate, progression free survival time, and frequency and degree of toxicity	—

Countries

Japan

Contacts

Public ContactHideomi Yamashita

University of Tokyo Hospital Department of Radiology

yamachan07291973@yahoo.co.jp03-5800-8667

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026